Agilent Navigates Market Challenges: Q3 Exceeds Expectations As Strategic Investments Pay Off
Agilent Navigates Market Challenges: Q3 Exceeds Expectations As Strategic Investments Pay Off
The Diagnostics and Genomics Group (DGG) revenue stood at $385 million, down 9% Y/Y (-8% Y/Y core), with an operating margin of 18.3%.Agilent Technologies, Inc. (NYSE:A) shares are trading higher after the company reported third-quarter results yesterday.
安捷倫科技公司（紐約證券交易所代碼：A）昨天公佈第三季度業績後，股價走高。
Revenue fell 5.6% Y/Y to $1.58 billion, beating the consensus of $1.56 billion. By segment, the Life Sciences and Applied Markets Group (LSAG) segment reported revenue of $782 million, down 8% Y/Y (-7% Y/Y core), with an operating margin of 28.4%.
收入同比下降5.6％，至15.8億美元，超過了市場普遍預期的15.6億美元。按細分市場劃分，生命科學與應用市場集團（LSAG）板塊報告的收入爲7.82億美元，同比下降8％（同比下降7％），營業利潤率爲28.4％。
The Agilent CrossLab Group (ACG) revenue came in at $411 million, up 4% Y/Y (+5% Y/Y core), with an operating margin of 34.0%.
安捷倫CrossLab集團（ACG）收入爲4.11億美元，同比增長4％（核心收入同比增長5％），營業利潤率爲34.0％。
The Diagnostics and Genomics Group (DGG) revenue stood at $385 million, down 9% Y/Y (-8% Y/Y core), with an operating margin of 18.3%.
診斷和基因組學集團（DGG）收入爲3.85億美元，同比下降9％（同比下降8％），營業利潤率爲18.3％。
As of July 31, cash and cash equivalents stood at $1.78 billion. Adjusted EPS of $1.32 surpassed the street view of $1.26.
截至7月31日，現金及現金等價物爲17.8億美元。調整後的每股收益爲1.32美元，超過了1.26美元的街景。
Outlook: Agilent forecasts fourth-quarter revenue of $1.641 billion – $1.691 billion (vs. $1.67 billion estimate) and adjusted EPS of $1.38 – $1.42 (vs. street view of $1.44).
展望：安捷倫預測第四季度收入爲16.41億美元至16.91億美元（估計爲16.7億美元），調整後的每股收益爲1.38美元至1.42美元（街景爲1.44美元）。
For FY24, Agilent revised its revenue outlook to $6.45 billion – $6.5 billion from $6.42 billion – $6.5 billion (vs. $6.46 billion estimate) and adjusted EPS to $5.21 – $5.25 (vs. $5.20 estimate) from $5.15 – $5.25 earlier.
對於24財年，安捷倫將其收入前景從64.2億美元至65億美元（估計爲64.6億美元）上調至64.5億美元——65億美元，調整後的每股收益從之前的5.15美元至5.25美元（預期爲5.20美元）。
Agilent President and CEO Padraig McDonnell said, "While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated. We continue to make investments in our most promising growth opportunities."
安捷倫總裁兼首席執行官帕德雷格·麥克唐納表示：「儘管本季度市場狀況繼續受到挑戰，但正如預期的那樣，我們看到了穩步改善的跡象。我們將繼續對最有前途的增長機會進行投資。」
"And we are mobilizing the organization to accelerate value creation through strategic transformation initiatives, which will drive margin expansion and growth—and increase our execution capabilities."
「而且我們正在動員組織通過戰略轉型計劃加快價值創造，這將推動利潤擴張和增長，並提高我們的執行能力。」
Investors can gain exposure to the stock via ProShares Nanotechnology ETF (NYSE:TINY) and VanEck ETF Trust VanEck Morningstar Wide Moat Growth ETF (BATS:MGRO).
投資者可以通過ProShares納米技術ETF（紐約證券交易所代碼：TINY）和VanEck ETF信託基金VanEck Morningstar Wide Morningstar Wide Morningstar Wide Morningstar Growth ETF（BATS: M
Price Action: A shares are up 1.88% at $142.63 at the last check Thursday.
價格走勢：在週四的最後一次檢查中，A股上漲1.88％，至142.63美元。
Image from Shutterstock
圖片來自 Shutterstock
- EHang Q2 Revenue Skyrockets 920% with Record eVTOL Deliveries: Details
- 億航第二季度收入猛增920％，eVTOL交付量創歷史新高：詳情
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：此內容部分是在人工智能工具的幫助下製作的，並由Benzinga的編輯審閱和發佈。
譯文內容由第三人軟體翻譯。
